BridgeBio Pharma, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
AstraZeneca's Phase 3 trial for a heart disease drug (a silencer) failed, showing no benefit for patients already on stabilizers. The study involved ATTR-CM patients and was conducted with Ionis Pharmaceuticals. The results may impact other companies like Alnylam and BridgeBio, which also market ATTR-CM drugs.
BridgeBio Pharma (BBIO) dosed the first participant in the ASCENT-ATTR Phase 3b/4 study of Acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). The trial aims to evaluate long-term effects, with primary endpoint being improvement in left ventricular systolic function at 36 months. Acoramidis is designed to stabilize transthyretin, potentially reducing amyloid deposits. BBIO shares are currently at $80.24, down 0.20%.
BridgeBio Pharma (BBIO) reported a 120% year-over-year revenue increase to $243.7M in Q2, driven by Attruby sales. The company's loss widened to $0.78 per share due to rising R&D and commercialization expenses. BBIO's cash position supports upcoming product launches, with management focusing on Attruby's market share gains.
Over the past 7 days, alphai's AI scored 6 news stories mentioning BBIO (BridgeBio Pharma, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.
Recent BBIO coverage spans technology, earnings and insider activity.
In the last 30 days, BBIO insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($3.9M). The most active reporter was Kumar Neil, Chief Executive Officer, with 7 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive perception for stabilizer class may boost BridgeBio's prospects.
First-in-human dosing may signal progress toward potential FDA approval, supporting a long‑term upside thesis.
Earnings beat on revenue with loss widening may cause short-term volatility; growth in Attruby sales supports upside.
BridgeBio may gain market access as PBM transparency improves.
Bearish call pressure could weigh on BBIO.
alphai scores every news story that mentions BBIO with an AI model for sentiment and relevance, and aggregates insider trades from BridgeBio Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AstraZeneca's Phase 3 trial for a heart disease drug (a silencer) failed, showing no benefit for patients already on stabilizers. The study involved ATTR-CM patients and was conducted with Ionis Pharmaceuticals. The results may impact other companies like Alnylam and BridgeBio, which also market ATTR-CM drugs.
2 min readBridgeBio Pharma (BBIO) dosed the first participant in the ASCENT-ATTR Phase 3b/4 study of Acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). The trial aims to evaluate long-term effects, with primary endpoint being improvement in left ventricular systolic function at 36 months. Acoramidis is designed to stabilize transthyretin, potentially reducing amyloid deposits. BBIO shares are currently at $80.24, down 0.20%.
2 min readBridgeBio Pharma (BBIO) reported a 120% year-over-year revenue increase to $243.7M in Q2, driven by Attruby sales. The company's loss widened to $0.78 per share due to rising R&D and commercialization expenses. BBIO's cash position supports upcoming product launches, with management focusing on Attruby's market share gains.
3 min readThe ATTR-CM market is changing in 2026 due to new treatments and regulatory shifts. Pfizer's tafamidis faces competition from BridgeBio's Attruby and Alnylam's Amvuttra. Regulatory scrutiny of PBMs may impact access to newer therapies, with patient advocacy groups and economists monitoring the situation. Industry analysts suggest competition could lower costs and improve outcomes, depending on PBM transparency reforms.
3 min readBenzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readKumar Neil (Chief Executive Officer) sold 10,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $84.03 ($83.86–$85.65, $0.84M total) across 3 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readKumar Neil (Chief Executive Officer) sold 34,980 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $82.53 ($81.15–$83.77, $2.89M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readBridgeBio (BBIO) reported Q2 2026 revenue of $243.7M, up from $110.6M last year, driven by Attruby sales. Net loss was $152.2M, down from $181.9M. The company has $1.7B in cash, with three potential product launches planned. FDA accepted NDAs for BBP-418 and Encaleret, with target action dates in late 2026 and 2027, respectively. Management expects improving operating performance and potential profitability in 2027.
3 min readBridgeBio Pharma (BBIO) completed a $390M equity offering at $78/share, reporting Q2 2026 revenue of $243.68M and a net loss of $152.22M. The company highlighted progress in its rare-disease pipeline, including FDA Priority Review for BBP-418 with a PDUFA date of November 27, 2026. Analysts project rapid revenue growth but no profitability by 2029.
3 min readBridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., August 13, 2026 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused
2 min read
